This report compiles 23 market-moving events that could play out in February with forward-looking, investigative reporting on each.
A sampling of headlines:
• Sangamo’s Phase I SB-913 study in MPS II unlikely to see neurological disease changes but somatic manifestations have better chance
• FibroGen/AstraZeneca’s roxadustat for anemia in CKD holds expert reservations on CV outcomes contrary to market enthusiasm
• Inventiva’s addition of PPAR gamma to lanifibranor’s targets has unclear value in NASH, triggering uncertainty over Phase II success